CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
A phase 2 trial of Relmacabtagene autoleucel in hodgkin lymphoma and non-hodgkin lymphoma, run by Shanghai Ming Ju Biotechnology Co., Ltd., now recruiting.
Overview
CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma is a phase 2 interventional study registered as NCT06479356 by Shanghai Ming Ju Biotechnology Co., Ltd., with 12 participants planned, started 2024-08-15 and due to reach its primary completion in 2025-04-30. Interventions recorded: Relma-cel. Conditions listed: Non-Hodgkin Lymphoma, Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialRelmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
Shares Relmacabtagene autoleucel, JW Therapeutics.
- TrialRELIANCE
Shares Relmacabtagene autoleucel, JW Therapeutics.
- TrialT-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- CompanyWuXi AppTec
Shares Relmacabtagene autoleucel, JW Therapeutics.
- TrialA Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Ly
- TrialA Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients
- TrialA Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
- TrialA Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treat